Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Ovarian Neoplasms 43Lung Neoplasms 41Fallopian Tube Neoplasms 29Carcinoma, Ovarian Epithelial 28Breast Neoplasms 22Neuroblastoma 18Adenocarcinoma of Lung 17Central Nervous System Neoplasms 16Brenner Tumor 12Endometrial Neoplasms 9Adenocarcinoma, Bronchiolo-Alveolar 9Testicular Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Astrocytoma 8Unspecified Adult Solid Tumor, Protocol Specific 7Triple Negative Breast Neoplasms 7Oligodendroglioma 7Lymphoma, Large B-Cell, Diffuse 7Brain Neoplasms 7Head and Neck Neoplasms 6Teratoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Medulloblastoma 5Leukemia, Myeloid, Acute 5Gliosarcoma 5Glioblastoma 5Thrombocythemia, Essential 4Testicular Germ Cell Tumor 4

Interventions

Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hemoptysis × Carboplatin × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡